The Life After Stopping Tyrosine Kinase Inhibitors Study (The LAST Study)
Public ClinicalTrials.gov record NCT02269267. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Brief summary
Reproduced verbatim from the official ClinicalTrials.gov record. Not medical advice.
This is a non-randomized, prospective, single-group longitudinal study. The purpose of this study is to improve the decision making process used by physicians and patients when they are considering stopping their Tyrosine Kinase Inhibitor (TKI) medication.
Study identification
- NCT ID
- NCT02269267
- Recruitment status
- Completed
- Study type
- Interventional
- Phase
- Phase 2
- Enrollment
- 173 participants
Conditions and interventions
Conditions
Interventions
- Imatinib (Stopping their TKI) Drug
- Dasatinib (Stopping their TKI) Drug
- Nilotinib (Stopping their TKI) Drug
- Bosutinib (Stopping their TKI) Drug
Drug
Eligibility (public fields only)
- Age range
- 18 Years and older
- Sex
- All
- Healthy volunteers
- Healthy volunteers not accepted
This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.
Study timeline
- Start date
- Dec 17, 2014
- Primary completion
- Apr 5, 2021
- Completion
- Apr 5, 2022
- Last update posted
- Mar 2, 2023
2014 – 2022
United States locations
- U.S. sites
- 16
- U.S. states
- 12
- U.S. cities
- 14
| Facility | City | State | ZIP | Site status |
|---|---|---|---|---|
| Helen Diller Family Comprehensive Cancer Center University of California | San Francisco | California | 94143 | — |
| Moffit Cancer Center | Tampa | Florida | 33612 | — |
| Winship Cancer Institute of Emory University | Atlanta | Georgia | 30322 | — |
| The University of Chicago | Chicago | Illinois | 60637 | — |
| The University of Chicago Medicine Comprehensive Cancer Center at Silver Cross | New Lenox | Illinois | 60451 | — |
| Beth Israel Deaconess Medical Center (Satellite site of Dana Farber) | Boston | Massachusetts | 02215 | — |
| Dana Farber Cancer Institute | Boston | Massachusetts | 02215 | — |
| Karmanos Cancer Institute of Wayne State University | Detroit | Michigan | 48201 | — |
| Roswell Park Cancer Institute | Buffalo | New York | 14263 | — |
| Weill Medical College of Cornell University | New York | New York | 10021 | — |
| Memorial Sloan Kettering Cancer Center | New York | New York | 10065 | — |
| Duke University Medical Center | Durham | North Carolina | 27710 | — |
| MD Anderson Cancer Center | Houston | Texas | 77054 | — |
| University of Utah Huntsman Cancer Institute | Salt Lake City | Utah | 84132-2408 | — |
| Fred Hutchinson Cancer Research Center | Seattle | Washington | 98109-1024 | — |
| Froedtert Hospital & Medical College of Wisconsin | Milwaukee | Wisconsin | 53226 | — |
Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.
About this trial record page
- What this page shows
- Public field values for ClinicalTrials.gov record NCT02269267, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
- What this page does not do
- No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
- Where the data comes from
- Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
- Last refresh
- Last update posted Mar 2, 2023 · Synced Sep 8, 2026
Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.
Open the official record
The complete protocol, eligibility criteria, and contact information for NCT02269267 live on ClinicalTrials.gov.